sci-agents-medical-specialties

Plugin sci-agents-medical-specialties from marketplace plugin-place in galeep/plugin-place. Commands read from the repo's manifest — today.

Subagents (54)

• anatomist

  Anatomist: Reasons from homology, EPB, and von Baer principles through gross dissection, diceCT/μCT/MRI pipelines, UBERON–PATO EQ annotation, MorphoSource/oVert digitization, geometric morphometrics, and NAV/TA2 nomenclature while treating fixation shrinkage, segmentation artifacts, landmark homolog

• anesthesiologist

  Anesthesiologist: Reasons from control of consciousness, analgesia, autonomic response, and oxygen delivery through the ASA Difficult Airway Algorithm, capnography and arterial-waveform trends, quantitative TOF monitoring, and ASRA/ERAS protocols while treating cannot-ventilate airways, local anesth

• audiologist

  Audiologist: Reasons from auditory transduction, site-of-lesion localization, audibility, and noise dose-response through calibrated pure-tone/masking audiometry, immittance, OAE and ABR/ASSR, and real-ear verification against NAL-NL2/DSL targets while treating unmasked cross-hearing, collapsed ear

• cancer-biologist

  Cancer Biologist: Reasons from hallmark capabilities, clonal evolution, and TME context; separates driver from passenger, cell-autonomous from stromal mechanisms, and 2D artifacts from PDO/PDX-validated dependencies using TCGA, DepMap, OncoKB, and REMARK-grade biomarker logic.

• cardiologist

  Cardiologist: Reasons from oxygen supply-demand mismatch, forward flow, filling pressures, and pre-test probability through 12-lead ECG, TTE/TEE with ASE grading, cath hemodynamics, CMR, and ACC/AHA/ESC guidelines with risk scores like HEART, GRACE, and CHA2DS2-VASc, while treating context-free trop

• clinical-embryologist

  Clinical Embryologist: Reasons from gamete and embryo biology, manufacturing-quality lab control, and prespecified cycle/oocyte/embryo denominators through Vienna consensus KPIs, Gardner/ASEBIR grading, time-lapse morphokinetics, WHO 6th-edition andrology, and vitrification SOPs while treating media

• clinical-laboratory-scientist

  Clinical Laboratory Scientist: Reasons from pre-analytical–analytical–post-analytical total testing process; EP15/EP09/EP28 validation, Westgard/Sigma IQC, HIL indices (C56), EP23/IQCP, critical-value read-back, type-and-screen/crossmatch, CLSI M100 direct AST, LC-MS/MS C62, and AUTO10 autoverificat

• clinical-pharmacologist

  Clinical Pharmacologist: Reasons from exposure–response, popPK (NONMEM), DDI (ICH M12), TDM/NTI windows, and renal/hepatic/allometric adjustment; aligns dose finding with ICH E4 and FDA clinical pharmacology labeling.

• comparative-medicine-researcher

  Comparative Medicine Researcher: Reasons from species biology, translational validity, and the 3Rs through model-validity frameworks, IACUC protocols, ARRIVE 2.0 reporting, and FELASA/AALAS health surveillance while treating substrain drift, subclinical colony infection (murine norovirus, pinworm, M

• critical-care-researcher

  Critical Care Researcher: Reasons from acute physiology trajectories, modular organ dysfunction, and cluster-aware trial design through APACHE/SAPS/SOFA scoring, Berlin/Sepsis-3/KDIGO definitions, MIMIC-IV phenotyping, and target-trial emulation with clone-censor-weighting while treating immortal-ti

• dentist-scientist

  Dentist-Scientist: Reasons from oral biofilm-host ecology, tissue healing capacity, and patient-level clinical endpoints (DMFS, PD/CAL, implant survival) through PICO/PROSPERO protocols, CAMBRA and 2017 AAP/EFP staging, ISO 4049/14801 bench tests with thermocycling, and GRADE-rated reviews while tre

• dermatologist

  Dermatologist: Clinical-research dermatologist: layered skin anatomy, inflammatory dermatoses and trial endpoints, dermoscopy vs clinical ABCDE, biopsy/pathology, patch testing, telederm, AAD guidelines, and topical steroid potency.

• developmental-biologist

  Developmental Biologist: Reasons from stage, positional information, gene regulatory networks, and tissue mechanics through morphology-based staging (Carnegie/HH/Theiler/NF/hpf), French-flag morphogen logic, light-sheet 4D imaging, lineage tracing, and ARRIVE/MDAR/REMBI reporting while treating deve

• digital-pathology-scientist

  Digital Pathology Scientist: Reasons from whole-slide pixels, pathologist-ground-truth label levels, and stain/scanner batch effects through QuPath, CLAM/TIAToolbox MIL, Macenko/Vahadane normalization, and MI-CLAIM/TRIPOD+AI standards while treating patch-level leakage, scanner-ID shortcuts, attenti

• ecotoxicologist

  Ecotoxicologist: Reasons from bioavailability (BLM/WHAM), OECD 201–222 tiered tests, and ECx/SSD HC5–PNEC derivation; compares PEC/PNEC under REACH/PPP frames while treating third-phase BCF artifacts, mixture CA departures, and mesocosm exposure mismatch as first-class failure modes.

• emergency-medicine-researcher

  Emergency Medicine Researcher: ED trial design expert for pragmatic and cluster RCTs, time-zero and immortal-time bias in acute cohorts, NIHSS/SOFA/qSOFA and ESI/CTAS triage, NEDS/NHAMCS registries, and CONSORT/SPIRIT reporting with Hawthorne and selection-bias failure modes.

• endocrinologist

  Endocrinologist: Start with the axis, not the number. Every hormone sits in a loop: hypothalamus → Keep the major axes distinct: HPA: CRH → ACTH → cortisol (and adrenal androgens). HPT: TRH → TSH → T4/T3; peripheral deiodinases and T3 receptor signaling.

• exercise-physiologist

  Exercise Physiologist: Reason from the Fick principle and verified gas exchange: separate VO2max, VT1/RCP, MLSS, and lactate kinetics before metabolic carts, biopsy, MRS, or periodization prescriptions.

• gene-therapy-scientist

  Gene Therapy Scientist: Reasons from vector biology, biodistribution, linked potency, and integration risk through ddPCR titer, empty/full analytics, ISA and off-target NGS (GUIDE-seq, CIRCLE-seq), and ICH S12 nonclinical design while treating pre-existing capsid neutralizing antibodies, RCV/RCA/RCR

• gerontologist

  Gerontologist: Reasons from senescence hallmarks, frailty, multi-morbidity, and life-course exposures through validated instruments (Fried phenotype, Rockwood CFS, SPPB/gait speed), epigenetic clocks (Horvath, PhenoAge, GrimAge), competing-risk survival (Fine-Gray), and NIA cohorts (HRS, NHATS, ITP)

• green-chemist

  Green Chemist: Reasons from Anastas–Warner 12 principles, Trost atom economy, and PMI/MMI/E-factor mass metrics; selects solvents via CHEM21/GSK/ACS GCIPR guides, integrates catalysis and LCA (ISO 14040), and aligns REACH/CSS with ACS GC&E benchmarking.

• hematologist

  Hematologist: Reasons from hematopoietic hierarchy, clonal evolution, and hemostatic balance through peripheral smear review, reticulocyte production index, flow cytometry, mixing studies, and WHO/ICC-anchored NGS and cytogenetics, while treating pseudothrombocytopenia, preanalytic line-draw and EDT

• hepatologist

  Hepatologist: Reasons from hepatic injury pattern (R-value), synthetic function, and portal hypertension through Child-Pugh/MELD 3.0, FIB-4 and elastography, LI-RADS/BCLC staging, SAAG paracentesis, and Baveno VII criteria while treating DILI misattribution, elastography false positives in cholestas

• immunotherapy-scientist

  Immunotherapy Scientist: Reasons from antigen recognition and checkpoint circuits through CAR-T/bispecific design, ASTCT CRS/ICANS grading, flow cytometry release CQAs, iRECIST response assessment, COMPASS/TIDE biomarker modeling, and JACIE/FACT IEC accreditation while treating antigen escape, pseud

• infectious-disease-specialist

  Infectious Disease Specialist: Reasons from the host-pathogen-antimicrobial triangle, source control, and local resistance through IDSA/CLSI M100 breakpoints, PK/PD targets (vancomycin AUC24 400-600, beta-lactam time-above-MIC), and diagnostics like MALDI-TOF, BioFire panels, and galactomannan while

• medical-geneticist

  Medical Geneticist: Reasons from pedigree priors, HPO phenotype match, and ACMG/ClinGen variant classification; integrates exome/genome, CMA, RNA splicing, NBS ACT pathways, Tier 3 carrier screening, SF v3.3, and CPIC pharmacogenomics while treating VUS overcall, CPM/NIPT discordance, mtDNA heteropl

• medical-physicist

  Medical Physicist: Reasons from CTDIvol/SSDE, HU accuracy, ACR/MQSA QA, TG-126 PET/CT, TG-18/TG-270 displays, and NCRP 147 shielding across CT, MRI, mammography, NM/PET, and therapy QA while treating phantom-mismatch dose claims, SUV normalization drift, display washout, and post-upgrade MEE gaps as

• molecular-pathologist

  Molecular Pathologist: Reasons from tumor cellularity, assay-specific LOD, and AMP/ASCO/CAP Tier I–IV classification; validates IHC (CAP ≥90% concordance), FISH (HER2/ALK break-apart), and NGS oncology panels under CAP/CLIA MM09 while treating FFPE deamination, HER2-low/ultralow scoring, PD-L1 TPS v

• neuroanatomist

  Neuroanatomist: Stereotaxic targeting and skull leveling, Paxinos/Allen atlases, anterograde/retrograde tracing, Nissl vs IHC, BrainGlobe/QuickNII registration, and injection-spread or fibers-of-passage artifacts.

• neuroendocrinologist

  Neuroendocrinologist: Reasons from hypothalamic–pituitary portal axes (HPA, HPG, HPT), KNDy/GnRH pulsatility, SCN circadian gating, and SON/PVN neuropeptide release; uses HypoMap/HYPOMAP, stereotaxics with opto/chemogenetics, validated ELISA/RIA/FCM and LC-MS/MS, CoAL/CAR reporting, while treating b

• neurologist

  Neurologist: Reasons from anatomic localization, time course, and phenomenology through NIHSS/ASPECTS stroke triage, ILAE 2025 seizure classification, McDonald 2017 and AQP4/MOG cell-based assays, EEG and EMG/NCS, and SNOOP4 red flags, while treating CT-negative early ischemia, ~50%-sensitive routin

• neuropharmacologist

  Neuropharmacologist: Reasons from Kp,uu,brain and receptor occupancy, radioligand binding with depletion-aware Ki, biased GPCR/allosteric signaling, PDSP/GtoPdb panels, microdialysis and PET RO, and operant self-administration while treating Cheng-Prusoff error, P-gp efflux, FST validity limits, and

• nuclear-medicine-scientist

  Nuclear Medicine Scientist: Reasons from radioactive decay, biodistribution kinetics, and detector physics through HPLC/TLC radiochemical-purity QC, dose-calibrator cross-calibration, OSEM/PSF reconstruction, and MIRD/OLINDA dosimetry while treating partial-volume effects, attenuation mismatch, 68Ge

• oncologist

  Oncologist: Stages with AJCC TNM and molecular prognostic groups, selects biomarker-matched therapy from NCCN guidelines, assesses response with RECIST 1.1/iRECIST, and interprets trial endpoints with calibrated clinical judgment.

• ophthalmologist

  Ophthalmologist: Reasons from structure–function pairing (OCT RNFL/CST, HVF MD/VFI, ETDRS BCVA); manages glaucoma IOP targets and anti-VEGF treat-and-extend while treating field learning effect, OCT floor effect, and 15-letter regulatory margins as first-class failure modes.

• palliative-care-researcher

  Palliative Care Researcher: Reasons from serious-illness trajectories, multidimensional symptom burden, goals-of-care concordance, and caregiver dyad outcomes through validated PROMs (ESAS-r, IPOS, FACIT-Pal), prespecified MCID responder analysis, mixed-effects and joint survival-QoL models, and CON

• pathologist

  Pathologist: Reasons from H&E morphology, pretest-probability differentials, and pre-analytic integrity through CAP synoptic protocols, staged IHC and FISH panels, WHO/AJCC grading and staging, and Bethesda/Paris/Milan cytology systems while treating crush artifact, fixation/decalcification failure,

• pharmaceutical-formulation-scientist

  Pharmaceutical Formulation Scientist: Anchor every decision in the QTPP and critical quality attributes (CQAs): assay, Classify the API before choosing a technology path. Use BCS (solubility vs.

• pharmacokineticist

  Pharmacokineticist: Reasons from mass balance, exposure-response, and separation of structural from statistical models through NCA in Phoenix WinNonlin, mixed-effects popPK in NONMEM, PBPK in Simcyp/GastroPlus, and VPC diagnostics while treating BLQ mishandling, ETA shrinkage, over-parameterization

• pharmacologist

  Pharmacologist: Reasons from receptor occupancy, Black–Leff τ, EC50/IC50/Kd/Ki distinctions, Schild/Cheng–Prusoff antagonism, allosteric PAM/NAM cooperativity, GPCR bias, and PK/PD linkage; interprets binding/functional/HTS via GtoPdb/ChEMBL while treating spare receptors, radioligand depletion, and

• physician-scientist

  Physician-Scientist: Reasons across the bedside–bench cycle and T0–T4 spectrum; navigates PSTP/ABIM pathways, K08/K23/R01 funding, IRB/IND/IDE sponsor-investigator duties, and CONSORT/SPIRIT reporting while treating protected-time loss and preclinical irreproducibility as first-class failure modes.

• plant-pathologist

  Plant Pathologist: Reasons from the disease triangle, sign vs. symptom, and trophic strategy (biotroph/necrotroph/hemibiotroph); runs clinic-to-Koch workflows (TWA isolation, Phytophthora pear baiting, Baermann nematodes, EPPO PM7/qPCR with matrix-specific Ct cutoffs) and epidemic analysis (AUDPC/AU

• radiation-oncology-physicist

  Radiation Oncology Physicist: Reasons from absorbed dose, fluence, beam geometry, and constraint-driven plan quality through TG-51/TRS-398 reference dosimetry, TPS engines (AAA, Acuros XB, Monte Carlo), DVH metrics, and gamma-based patient-specific QA while treating stale CT-to-density tables, couch

• radiochemist

  Radiochemist: Reasons from radionuclide half-life, specific activity, radiochemical purity, and dosimetry through analytical/prep HPLC with radiodetector, iTLC, HPGe γ-spectroscopy, OLINDA/MIRD, and USP <823>/EANM release specs while treating defluorination, transchelation of ⁶⁸Ga/⁸⁹Zr, ⁹⁹ᵐTc colloi

• radiologist

  Radiologist: Reasons from modality–question fit, contrast kinetics, and ACR Appropriateness Criteria (1–9); applies BI-RADS, LI-RADS, PI-RADS, and Lung-RADS with Fleischner/incidental-findings algorithms; integrates PACS/RIS/DICOM/IHE workflows, CTDIvol/DLP/DIR dose stewardship, and critical-results

• regenerative-medicine-scientist

  Regenerative Medicine Scientist: Reasons from potency assurance, 361 vs 351/ATMP pathways, USP <1043> ancillary tiers, G-Rex/closed CAR-T manufacture, MSC matrix potency, and ISO 10993/dECM scaffolds while treating comparability-without-bioassay and CFU-F-as-potency as first-class failure modes.

• rehabilitation-scientist

  Rehabilitation Scientist: Reasons from ICF/disablement models, COSMIN MCID/MDC triangulation, TIDieR-Rehab/CONSORT 2025 trial design, gait lab and PROMIS outcomes, motor-learning mechanisms, and RE-AIM implementation science; treats natural recovery, therapist allegiance, and lab-vs-function confoun

• reproductive-biologist

  Reproductive Biologist: Reasons from the HPG axis, gametogenesis, embryo development, and endometrial receptivity through WHO 6th semen analysis, LC-MS/MS hormone assays, EmbryoScope morphokinetics, PGT-A, and ASRM/ESHRE guidelines while treating mis-timed cycle-day sampling, incubator CO2/pH drift,

• sleep-scientist

  Sleep Scientist: Reasons from Borbély Process S/C homeostatic–circadian integration, AASM v3 PSG scoring (1A/1B hypopnea rules), DLMO/forced desynchrony phase assays, MSLT/ICSD-3 hypersomnolence criteria, Cole-Kripke/Sadeh actigraphy, NSRR/SHHS cohorts, and CBT-I/CPAP trial design while treating fir

• sports-scientist

  Sports Scientist: Reasons from periodization and session-RPE/ACWR/GPS load monitoring, VALD force-plate readiness, SWC/TE decision bands, and IOC/STROBE-SIIS/CERT/CONSORT reporting while treating pseudoreplication, Hawthorne reactivity, and single-metric injury claims as first-class failure modes.

• surgeon-scientist

  Surgeon-Scientist: Reasons from anatomy, pathophysiology, and the IDEAL stage of surgical innovation through IDE/IND pathways, NSQIP/STS registry risk-adjustment, CUSUM learning-curve analysis, and ischemia-timed biobank SOPs while treating unrisk-adjusted case series, indication-confounded surgeon-

• toxicologist

  Toxicologist: Reasons from dose–response, ADME/TK, MOA/AOP, and exposure context; separates hazard from risk; derives BMDL/DNEL/RfD PODs and interprets OECD/ICH batteries with vehicle, strain, S9, and histopath artifacts as first-class failure modes.

• vaccinologist

  Vaccinologist: Vaccine development expert for platform and adjuvant selection, validated immunogenicity (HAI/PRNT/OPA), CoP and immunobridging, VE/effectiveness trial design, CBER lot release, and Brighton AEFI reporting.

• veterinary-epidemiologist

  Veterinary Epidemiologist: Reasons from herd-level units, Rogan–Gladen prevalence, R₀/SIR transmission models, and WOAH freedom-from-disease surveillance through outbreak line lists, SaTScan clusters, cluster field trials (REFLECT), and STROBE-Vet/AHSURED reporting while treating pseudo-replication,

Similar plugins